UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Clinical cancer research, 2018-12, Vol.24 (23), p.5841-5849

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Journal of clinical oncology, 2020-01, Vol.38 (3), p.193-202

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

The lancet oncology, 2018-07, Vol.19 (7), p.940-952

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The New England journal of medicine, 2013-07, Vol.369 (2), p.134-144

2013

Link zum Volltext

Verfügbarkeit prüfen

Formation of a Unique End-to-End Stacked Pair of G-Quadruplexes in the hTERT Core Promoter with Implications for Inhibition of Telomerase by G-Quadruplex-Interactive Ligands

Journal of the American Chemical Society, 2009-08, Vol.131 (31), p.10878-10891

2009

Link zum Volltext

Verfügbarkeit prüfen

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Clinical cancer research, 2010-04, Vol.16 (7), p.2167-2175

2010

Link zum Volltext

Verfügbarkeit prüfen

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2400-2407

2021

Link zum Volltext

Verfügbarkeit prüfen

Evidence for the Presence of a Guanine Quadruplex Forming Region within a Polypurine Tract of the Hypoxia Inducible Factor 1α Promoter

Biochemistry (Easton), 2005-12, Vol.44 (49), p.16341-16350

2005

Link zum Volltext

Verfügbarkeit prüfen

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity

Nucleic acids research, 2008-04, Vol.36 (6), p.1755

2008

Link zum Volltext

Verfügbarkeit prüfen

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)

Cancer chemotherapy and pharmacology, 2013-10, Vol.72 (4), p.909-916

2013

Link zum Volltext

Verfügbarkeit prüfen

Peptide nucleic acid conjugates: synthesis, properties and applications

Current topics in medicinal chemistry, 2005-10, Vol.5 (12), p.1119

2005

Link zum Volltext

Verfügbarkeit prüfen

PNA−Nitrogen Mustard Conjugates Are Effective Suppressors of HER-2/neu and Biological Tools for Recognition of PNA/DNA Interactions

Bioconjugate chemistry, 2006-01, Vol.17 (1), p.214-222

2006

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of PNA Transport to the Nuclear Compartment

Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.27-30

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract CN02-02: Dual inhibition of mTOR and IGFR pathways

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.CN02-02-CN02-02

Ebbinghaus, Scot W.

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Evaluation of a Triplex-Forming Oligonucleotide−Pyrrolobenzodiazepine Conjugate

Bioconjugate chemistry, 2004-11, Vol.15 (6), p.1182-1192

2004

Link zum Volltext

Verfügbarkeit prüfen

Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis

Hematology/oncology clinics of North America, 2004-10, Vol.18 (5), p.1143

2004

Link zum Volltext

Verfügbarkeit prüfen

Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif

Nucleic acids research, 2001-12, Vol.29 (23), p.4873

2001

Link zum Volltext

Verfügbarkeit prüfen

A Bis-Alkylating Triplex Forming Oligonucleotide Inhibits Intracellular Reporter Gene Expression and Prevents Triplex Unwinding Due to Helicase Activity

Biochemistry (Easton), 2003-05, Vol.42 (17), p.5013-5024

2003

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Transcription Elongation in the HER-2/neu Coding Sequence by Triplex-Directed Covalent Modification of the Template Strand

Biochemistry (Easton), 1999-01, Vol.38 (2), p.619-628

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1307: Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1307-1307

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1868-1868

2012

Link zum Volltext

Verfügbarkeit prüfen

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P103-P103, Article P103

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(41)
Buchkapitel
(1)

Sprache

Englisch
(42)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Formation of a Unique End-to-End Stacked Pair of G-Quadruplexes in the hTERT Core Promoter with Implications for Inhibition of Telomerase by G-Quadruplex-Interactive Ligands

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Evidence for the Presence of a Guanine Quadruplex Forming Region within a Polypurine Tract of the Hypoxia Inducible Factor 1α Promoter

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)

Peptide nucleic acid conjugates: synthesis, properties and applications

PNA−Nitrogen Mustard Conjugates Are Effective Suppressors of HER-2/neu and Biological Tools for Recognition of PNA/DNA Interactions

Mechanism of PNA Transport to the Nuclear Compartment

Abstract CN02-02: Dual inhibition of mTOR and IGFR pathways

Synthesis and Evaluation of a Triplex-Forming Oligonucleotide−Pyrrolobenzodiazepine Conjugate

Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis

Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif

A Bis-Alkylating Triplex Forming Oligonucleotide Inhibits Intracellular Reporter Gene Expression and Prevents Triplex Unwinding Due to Helicase Activity

Inhibition of Transcription Elongation in the HER-2/neu Coding Sequence by Triplex-Directed Covalent Modification of the Template Strand

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma

Abstract 1307: Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475)

Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

Suchergebnisse filtern